Ayesha Bint Umar Awan

Dr. Ayesha Bint Umar Awan

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Saudi Journal of Biological Sciences
Verified
Journal Article
Open access
Muhammad SarfrazMuhammad Sarfraz
Muhammad Sarfraz
KRKanwal Rehman
Kanwal Rehman
MTMUHAMMAD TARIQ
MUHAMMAD TARIQ
Muhammad GhoriMuhammad Ghori
Muhammad Ghori
KKKashif Maqbool Khan
Kashif Maqbool Khan
AAAyesha Bint Umar Awan
Ayesha Bint Umar Awan
This study was aimed to investigate the anticancer potential of Euphorbia milii (E. milii) using an exquisite combination of phytopharmacological and advanced computational techniques. The chloroform fraction (Em-C) of E. milii methanol extract showed the highest antioxidant activity (IC50: 6.41 ± 0.99 µg/ml) among all studied fractions. Likewise, Em-C also showed significant cytotoxicity (IC50: 11.2 ± 0.8 µg/ml) when compared with that of standard compound 5-fluorouracil (5-FU) (IC50: 4.22 ± 0.6 µg/ml) against hepatocarcinoma cell line (HepG2). However, in a human cervical cancer cell line (HeLa), Em-C demonstrated a non-significant difference in cytotoxicity (22.1 ± 0.8 µg/ml) when compared with that of 5-FU (IC50: 6.87 ± 0.5 µg/ml). Furthermore, Western blot and qRT-PCR analysis revealed that the suppression of HepG2 cells was the consequence of a tremendous decrease in CDK2 and E2F1 protein expression. The GC–MS analysis of Em-C revealed the unique presence of cyclobarbital (CBT) and benzodioxole derivative (BAN) as major constituents. Furthermore, molecular docking of compounds BAN, CBT, and MBT into the binding site of different molecular targets i.e. cyclin dependent kinase 2 (CDK2), thymidylate synthase (TS), caspase 3, BCL2 and topoisomerase II was carried out. Compounds BAN and CBT have demonstrated remarkable binding affinity towards CDK2 and thymidylate synthase, respectively. Molecular dynamic simulation studies have further confirmed the finding of docking analysis, suggesting that CDK2 and TS can act as an attractive molecular target for BAN and CBT, respectively. It can be concluded that these E. milii phytoconstituents (BAN and CBT) may likely be responsible for anti-invasive activity against HepG2 cells.

10 March 2023 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
ARAli Raza
Ali Raza
AAAyesha Bint Umar Awan
Ayesha Bint Umar Awan
MSMuhammad Sarfraz
Muhammad Sarfraz
TCTalha Ali Chohan
Talha Ali Chohan
MSMuhammad Imran Sajid
Muhammad Imran Sajid
HSHammad Saleem
Hammad Saleem
Fibroblast growth factor receptors 1 (FGFR1) is an emerging target for the development of anticancer drugs. Uncontrolled expression of FGFR1 is strongly associated with a number of different types of cancers. Apart from a few FGFR inhibitors, the FGFR family members have not been thoroughly studied to produce clinically effective anticancer drugs. The application of proper computational techniques may aid in understanding the mechanism of protein–ligand complex formation, which may provide a better notion for developing potent FGFR1 inhibitors. In this study, a variety of computational techniques, including 3D-QSAR, flexible docking and MD simulation followed by MMGB/PBSA, H-bonds and distance analysis, have been performed to systematically explore the binding mechanism of pyrrolo-pyrimidine derivatives against FGFR1. The 3D-QSAR model was generated to deduce the structural determinants of FGFR1 inhibition. The high q2 and r2 values for the CoMFA and CoMSIA models indicated that the created 3D-QSAR models could reliably predict the bioactivities of FGFR1 inhibitors. The computed binding free energies (MMGB/PBSA) for the selected compounds were consistent with the ranking of their experimental binding affinities against FGFR1. Furthermore, per-residue energy decomposition analysis revealed that the residues Lys514 in catalytic region, Asn568, Glu571 in solvent accessible portion and Asp641 in DFG motif exhibited a strong tendency to mediate ligand–protein interactions through the hydrogen bonding and Van Der Waals interactions. These findings may benefit researchers in gaining better knowledge of FGFR1 inhibition and may serve as a guideline for the development of novel and highly effective FGFR1 inhibitors. Communicated by Ramaswamy H. Sarma

12 December 2023 in Computational Biology and Chemistry
Verified
Journal Article
Closed access
IHIffat Habib
Iffat Habib
AAAyesha Bint Umar Awan
Ayesha Bint Umar Awan
TCTalha Ali Chohan
Talha Ali Chohan
FBFakhra Batool
Fakhra Batool
UKUmair Khurshid
Umair Khurshid
HSHammad Saleem
Hammad Saleem

11 March 2024 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
AAAndleeb Asghar
Andleeb Asghar
AAAyesha Bint Umar Awan
Ayesha Bint Umar Awan
UKUmair Khurshid
Umair Khurshid
HSHammad Saleem
Hammad Saleem
MMMian Waqar Mustafa
Mian Waqar Mustafa
SASirajudheen Anwar
Sirajudheen Anwar

28 October 2022 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
ARAli Raza
Ali Raza
TCTalha Ali Chohan
Talha Ali Chohan
MBManal Ali Buabeid
Manal Ali Buabeid
EAEl-Shaima A Arafa
El-Shaima A Arafa
AAAyesha Bint Umar Awan
Ayesha Bint Umar Awan
GMGhulam Murtaza
Ghulam Murtaza
Artificial intelligence (AI) development imitates the workings of the human brain to comprehend modern problems. The traditional approaches such as high throughput screening (HTS) and combinatorial chemistry are lengthy and expensive to the pharmaceutical industry as they can only handle a smaller dataset. Deep learning (DL) is a sophisticated AI method that uses a thorough comprehension of particular systems. The pharmaceutical industry is now adopting DL techniques to enhance the research and development process. Multi-oriented algorithms play a crucial role in the processing of QSAR analysis, de novo drug design, ADME evaluation, physicochemical analysis, preclinical development, followed by clinical trial data precision. In this study, we investigated the performance of several algorithms, including deep neural networks (DNN), convolutional neural networks (CNN) and multi-task learning (MTL), with the aim of generating high-quality, interpretable big and diverse databases for drug design and development. Studies have demonstrated that CNN, recurrent neural network and deep belief network are compatible, accurate and effective for the molecular description of pharmacodynamic properties. In Covid-19, existing pharmacological compounds has also been repurposed using DL models. In the absence of the Covid-19 vaccine, remdesivir and oseltamivir have been widely employed to treat severe SARS-CoV-2 infections. In conclusion, the results indicate the potential benefits of employing the DL strategies in the drug discovery process. Communicated by Ramaswamy H. Sarma

24 October 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
SASirajudheen Anwar
Sirajudheen Anwar
JAJowaher Alanazi
Jowaher Alanazi
NANafees Ahemad
Nafees Ahemad
SRShafaq Raza
Shafaq Raza
AAAyesha Bint Umar Awan
Ayesha Bint Umar Awan
HSHammad Saleem
Hammad Saleem
Introduction: The epidermal growth factor receptor (EGFR) presents a crucial target for combatting cancer mortality.Methods: This study employs a suite of computational techniques, including 3D-QSAR, ligand-based virtual screening, molecular docking, fingerprinting analysis, ADME, and DFT-based analyses (MESP, HOMO, LUMO), supplemented by molecular dynamics simulations and MMGB/PBSA free energy calculations, to explore the binding dynamics of quinazoline derivatives with EGFR. With strong q2 and r2 values from CoMFA and CoMSIA models, our 3D- QSAR models reliably predict EGFR inhibitors’ efficacy.Results and Discussion: Utilizing a potent model compound as a reference, an E-pharmacophore model was developed to sift through the eMolecules database, identifying 19 virtual screening hits based on ShapeTanimoto, ColourTanimoto, and TanimotoCombo scores. These hits, assessed via 3D- QSAR, showed pIC50 predictions consistent with experimental data. Our analyses elucidate key features essential for EGFR inhibition, reinforced by ADME studies that reveal favorable pharmacokinetic profiles for most compounds. Among the primary phytochemicals examined, potential EGFR inhibitors were identified. Detailed MD simulation analyses on three select ligands—1Q1, 2Q17, and VS1—demonstrated their stability and consistent interaction over 200 ns, with MM/GBSA values corroborating their docking scores and highlighting 1Q1 and VS1’s superior EGFR1 affinity. These results position VS1 as an especially promising lead in EGFR1 inhibitor development, contributing valuable insights towards crafting novel, effective EGFR1 inhibitors.